HETEROCYCLIC COMPOUNDS AND USES THEREOF

1 . A compound of Formula I:

or a pharmaceutically acceptable salt, a prodrug, solvate, a tautomer, an isomer or a deuterated analog thereof,

wherein:

(i) Y 2 is N and Y 3 is C; or

(ii) Y 2 is C and Y 3 is N;

Y 1 is CH or N;

L is a bond, optionally substituted C 1-6 alkylene, optionally substituted deuterated C 1-6 alkylene, —C(R 6 R 7 )—, C(O)NR 9 —, —CH 2 N(R 9 )—, —SO 2 N(R 9 )—, —N(R 9 )C(O)N(R 9 )—, —N(R 9 )SO 2 —, —N(R 9 )CH 2 —, —OC 1-4 alkylene-, —C 1-4 alkylene-O—, —NR 9 C(O)—, —N(R 9 )SO 2 —, —C(O)—, —S(O)—, —SO 2 —, —O—, —S—, —P(O)(R a )—, optionally substituted C 2-6 alkenylene, optionally substituted —CH═C(R b )— or optionally substituted Si(R c )(R c ); or R 6 and R 7 taken together with the carbon atom to which they attach form an optionally substituted 3- to 6-membered ring having from 0-2 heteroatoms selected from O, N or S or an oxo; R a is optionally substituted C 1-6 alkyl, optionally substituted aryl or optionally substituted heteroaryl; R b is H or C 1-6 alkyl; or R b and R 1 taken together with the carbon atom to which they attach form an optionally substituted 3- to 6-membered carbocyclic ring or an optionally substituted 4- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms can be optionally oxidized; each R c is independently C 1-6 alkyl or C 1-6 alkoxy; R 9 is H, C 1-4 alkyl or C 1-4 haloalkyl;

R 1 , R 2 , R 4 , R 6 and R 7 are each independently H, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkenyl, optionally substituted C 1-6 alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted cycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted Si(R c )(R c ) or R 13 selected from halogen, —CN, —OH, —NH 2 , —NO 2 , —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —CH═C(R g )(R g ), —OR g , —SR g , —OC(O)R g , —OC(S)R g , —P(═O)HR g , —P(═O)R g R g , —PH(═O)OR g , —P(═O)(OR g ) 2 , —OP(═O)(OR g ) 2 , —C(O)H, —O(CO)OR g , —C(O)R g , —C(S)R g , —C(O)OR g , —C(S)OR g , —S(O)R g , —S(O) 2 R g , —C(O)NHR g , —C(S)NHR g , —C(O)NR g R g , —C(S)NR g R g , —S(O) 2 NHR g , —S(O) 2 NR g R g , —C(NH)NHR g , —C(NH)NR g R g , —NHC(O)R g , —NHC(S)R g , —NR g C(O)R g , —NR g C(S)R g , —NHS(O) 2 R g , —NR g S(O) 2 R g , —NHC(O)NHR g , —NHC(S)NHR g , —NR g C(O)NH 2 , —NR g C(S)NH 2 , —NR g C(O)NHR g , —NR g C(S)NHR g , —NHC(O)NR g R g , —NHC(S)NR g R g , —NR g C(O)NR g R g , —NR g C(S)NR g R g , —NHS(O) 2 NHR g , —NR g S(O) 2 NH 2 , —NR g S(O) 2 NHR g , —NHS(O) 2 NR g R g , —NR g S(O) 2 NR g R g , —NHR g or —NR g R g , wherein each R g is independently H, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkenyl, optionally substituted C 1-6 alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted cycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted heterocycloalkylalkyl; or two R g groups when attached to the same carbon or nitrogen atom are taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms are optionally oxidized; wherein the aliphatic or aromatic portion of R g is optionally substituted with from 1-3 R h substituents independently selected from halogen, —CN, —OH, —NH 2 , —NO 2 , —CH═C(R k )(R k ), —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —OR i , —SR i , —OC(O)R i , —OC(S)R i , —P(═O)HR i , —P(═O)R i R i , —PH(═O)OR i , —P(═O)(OR i ) 2 , —OP(═O)(OR i ) 2 , —C(O)H, —O(CO)OR i , —C(O)R i , —C(S)R i , —C(O)OR i , —C(S)OR i , —S(O)R i , —S(O) 2 R i , —C(O)NHR i , —C(S)NHR i , —C(O)NR i R i , —C(S)NR i R i , —S(O) 2 NHR i , —S(O) 2 NR i R i , —C(NH)NHR i , —C(NH)NR i R i , —NHC(O)R i , —NHC(S)R i , —NR i C(O)R i , —NR i C(S)R i , —NHS(O) 2 R i , —NR i S(O) 2 R i , —NHC(O)NHR i , —NHC(S)NHR i , —NR i C(O)NH 2 , —NR i C(S)NH 2 , —NR i C(O)NHR i , —NR i C(S)NHR i , —NHC(O)NR i R i , —NHC(S)NR i R i , —NR i C(O)NR i R i , —NR i C(S)NR i R i , —NHS(O) 2 NHR i , —NR i S(O) 2 NH 2 , —NR i S(O) 2 NHR i , —NHS(O) 2 NR i R i , —NR i S(O) 2 NR i R i , R i , —NHR i or —NR i R i , wherein each R i is independently C 1-6 alkyl, aryl, aryl-C 1-2 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, heterocycloalkyl or heterocycloalkyl-C 1-4 alkyl, wherein each R i is further optionally substituted with from 1-3 R p groups independently selected from halogen, CN, —OH, —NH 2 , —N(R q )(R q ), —NO 2 , —C(O)OH, —C(O)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —C(NH)NH 2 , —P(═O)HR q , —P(═O)R q R q , —PH(═O)OR q , —P(═O)(OR q ) 2 , —OP(═O)(OR q ) 2 , —OC(O)R q , —OC(S)R q , —C(O)R q , —C(S)R q , —C(O)OR q , —S(O) 2 R q , —C(O)NHR q , C 1-6 alkyl, C 1-6 alkoxy, halogen, C 1-6 haloalkyl or C 1-6 haloalkoxy, wherein R q is C 1-6 alkyl;

R 3 is H, halogen, —CN, optionally substituted C 1-6 alkyl, optionally substituted aryl, optionally substituted aryl-C 1-4 alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-C 1-4 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 3-8 cycloalkenyl, optionally substituted C 3-8 cycloalkyl-C 1-4 alkyl, optionally substituted C 2-6 alkynyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkyl-C 1-4 alkyl or R j selected from halogen, —CN, —OH, —NH 2 , —NO 2 , —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —CH═C(R k )(R k ), —OR k , —SR k , —OC(O)R k , —OC(S)R k , —P(═O)HR k , —P(═O)R k R k , —PH(═O)OR k , —P(═O)(OR k ) 2 , —OP(═O)(OR k ) 2 , —C(O)H, —O(CO)OR k , —C(O)R k , —C(S)R k , —C(O)OR k , —C(S)OR k , —S(O)R k , —S(O) 2 R k , —C(O)NHR k , —C(S)NHR k , —C(O)NR k R k , —C(S)NR k R k , —S(O) 2 NHR k , —S(O) 2 NR k R k , —C(NH)NHR k , —C(NH)NR k R k , —NHC(O)R k , —NHC(S)R k , —NR k C(O)R k , —NR k C(S)R k , —NHS(O) 2 R k , —NR k S(O) 2 R k , —NHC(O)NHR k , —NHC(S)NHR k , —NR k C(O)NH 2 , —NR k C(S)NH 2 , —NR k C(O)NHR k , —NR k C(S)NHR k , —NHC(O)NR k R k , —NHC(S)NR k R k , —NR k C(O)NR k R k , —NR k C(S)NR k R k , —NHS(O) 2 NHR k , —NR k S(O) 2 NH 2 , —NR k S(O) 2 NHR k , —NHS(O) 2 NR k R k , —NR k S(O) 2 NR k R k , —NHR k or —NR k R k ; or two R k groups when attached to the same carbon or nitrogen atom are taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms are optionally oxidized; wherein each R k is independently H, C 1-6 alkyl or aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl or cycloalkylalkyl, wherein R k is optionally substituted with from 1-3 R h ;

R 5 is an optionally substituted 5- or 6-membered heteroaryl having from 1 to 4 heteroatoms as ring members selected from O, N or S; and

is a single bond or a double bond, with the proviso that the compound is other than 3,5-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)isoxazole.

2 . The compound of claim 1 , wherein

wherein R 6 and R 7 are each independently H, D, halogen, —OH, C 1-6 alkyl, deuterated C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, aryl-C 1-4 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl, heteroaryl, heteroarylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, R j , —OR d , —NR d R d , —C(O)OR d , —OC(O)R d , —OC(O)OR d , —C(O)R d , —NHC(O)R d , —C(O)NR d R d , —SO 2 R d , —NHSO 2 R d or —SO 2 NR d R d , wherein at each occurrence, R 6 or R 7 is further optionally substituted with from 1-3 independently selected R h members; wherein the aliphatic or aromatic portion of L is optionally substituted with from 1-3 R e substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, —OH, —CN, —NH 2 , vinyl, ethynyl, C 3-6 cycloalkyl, aryl, C 1-6 haloalkyl, C 1-6 haloalkoxy, —C(O)OR f , —OC(O)R f , —OC(O)OR f , —C(O)R f , —NHC(O)R f , —C(O)NR f R f , —SO 2 R f , —NHSO 2 R f or —SO 2 NR f R f ; R 9 is H, C 1-4 alkyl or C 1-4 haloalkyl; each R d is independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl or aryl, each of which is optionally substituted; each R f is independently H or C 1-6 alkyl.

3 . The compound of claim 1 or 2 , having formula (II):

4 . The compound of claim 1 or 2 , having formula (III):

5 . The compound of claim 1 or 2 , having formula (II):

6 . The compound of claim 1 or 2 , having formula (V):

7 . The compound of any of claims 1 - 6 , wherein Y 1 is N.

8 . The compound of any of claims 1 - 6 , wherein Y 1 is CH.

9 . The compound of claim 1 or 5 , wherein Y 2 is C and Y 3 is N.

10 . The compound of claim 1 or 5 , wherein Y 2 is N and Y 3 is C.

11 . The compound of any of claims 1 - 5 , wherein L is a bond, —CD 2 -, C 1-6 alkylene, —C(R 6 R 7 )—, —C(O)—, —S(O)—, —SO 2 —, —O—, —S—, —P(O)(R a )—, C 2-6 alkenylene, —CH═C(R b )— or —Si(R c )(R c ), wherein:

R 6 and R 7 are each independently H, halogen, —OH, C 1-6 alkyl, deuterated C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl, heteroaryl, heteroarylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, —OR d , —NR d R d , —C(O)OR d , —OC(O)R d , —OC(O)OR d , —C(O)R d , —NHC(O)R d , —C(O)NR d R d , —SO 2 R d , —NHSO 2 R d or —SO 2 NR d R d ; or R 6 and R 7 taken together with the carbon atom to which they attach form a 3- to 6-membered ring having from 0-2 heteroatoms selected from O, N or S; and

R b and R 1 taken together with the carbon atom to which they attach form a 3- to 6-membered carbocyclic ring or 4- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms can be optionally oxidized.

12 . The compound of any of claims 1 - 4 and 11 , wherein L is a bond, —CD 2 -, C 1-6 alkylene, —C(O)—, —S(O)—, —SO 2 —, —O—, —S—, —P(O)(C 1-6 alkyl)-, —P(O)(aryl)-, —CH(OH)—, —CHF—, —CF 2 —, —CH(C 1-6 alkyl)-, —C(OC 1-6 alkyl)-, —C(C 1-6 alkyl) 2 -, —CH(C 3-6 cycloalkyl)-, —CH(haloalkyl)-, —C(C 3-6 cycloalkyl) 2 -, C 2-6 alkenylene, —CH(R 8 )—, —C(C 1-6 alkyl)(R 8 )—, —CHCH═C(R b )— or —Si(R c )(R c ), wherein:

R b and R 1 taken together with the carbon atom to which they attach form an optionally substituted 3 to 6-membered cycloalkane or cyaloalkene ring or an optionally substituted 4- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms can be optionally oxidized;

each R 8 is independently selected from C 1-6 alkyl, haloalkyl, haloalkoxy, R d , —OR d , —NR d R d , —C(O)OR d , —OC(O)R d , —OC(O)OR d , —C(O)R d , —NHC(O)R d , —C(O)NR d R d , —SO 2 R d , —NHSO 2 R d or —SO 2 NR d R d ; wherein the aliphatic or aromatic portion of L is optionally further substituted with from 1-3 R e substitutents independently selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, —OH, —CN, —NH 2 , C 3-6 cycloalkyl, aryl, C 1-6 haloalkyl or C 1-6 haloalkoxy.

13 . The compound of any claims 1 - 4 and 11 - 12 , wherein L is a bond, —CH 2 —, —CD 2 -, —C(O)—, —C(OC 1-6 alkyl)-, —CH(C 1-6 alkyl)-, —C(C 1-6 alkyl) 2 -, —CH(OH)—, —CHF—, —S(O)—, —SO 2 —, —O—, —S—, —P(O)(C 1-6 alkyl)-, —P(O)(C 6 H 5 )—, —CH(C 3-6 cycloalkyl)-, —C(C 3-6 cycloalkyl) 2 -, —C(OH)(C 1-6 alkyl)-, —CH(COOH)—, —CH(CONR b )—, —Si(C 1-6 alkyl) 2 - or —CH(CD 2 OH)—, each of which is optionally substituted with from 1-3 R e groups.

14 . The compound of any of claims 1 - 13 , wherein R 5 is an optionally substituted 5-membered heteroaryl having from 2 to 4 heteroatoms as ring members selected from O, N or S.

15 . The compound of any of claims 1 - 14 , wherein R 5 is selected from:

each of which is optionally substituted, wherein the wavy line indicates the point of attachment to the rest of molecule.

16 . The compound of any of claims 1 - 15 , wherein R 5 is optionally substituted 4-isoxazolyl.

17 . The compound of any of claims 1 - 13 , wherein R 5 is an optionally substituted 6-membered heteroaryl having from 1 to 2 nitrogen atoms as ring members.

18 . The compound of any of claims 1 - 17 , wherein R 1 is H, halogen, deuterated C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with from 1-3 R j groups, wherein two R j substituents when attached to adjacent atoms of aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring are optionally taken together to form a 5- or 6-membered ring having from 0-2 heteroatoms selected from O, N or S, wherein the 5- or 6-membered ring is optionally substituted with from 1-3 R h groups; or two R 1 groups when attached to the same carbon or nitrogen atom are optionally taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms are optionally oxidized.

19 . The compound of any of claims 1 - 18 , wherein R 1 is H, halogen, deuterated C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with from 1-3 R h groups, wherein two R h substituents when attached to adjacent atoms of aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring are optionally taken together to form a 5- or 6-membered ring having from 0-2 heteroatoms selected from O, N or S, wherein the 5- or 6-membered ring is optionally substituted with from 1-3 members independently selected from halogen, C 1-6 alkyl, —OH, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, —CN, —NH 2 , —NH(C 1-6 alkyl) or —N(C 1-6 alkyl) 2 ; or two R h groups when attached to the same carbon or nitrogen atom are optionally taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms are optionally oxidized.

20 . The compound of any of claims 1 - 19 , wherein R 2 is H, C 1-6 alkyl, aryl, C 3-6 cycloalkyl, heteroaryl, heterocycloalkyl, each of which is optionally substituted with from 1-3 R j groups.

21 . The compound of any of claims 1 - 20 , wherein R 3 is H, halogen, —CN, —CD 3 , deuterated, C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 3-8 cycloalkyl-C 1-4 alkyl, C 2-6 alkynyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl or wherein each R 3 is optionally substituted with from 1-3 R m groups independently selected from CN, —OH, —NH 2 , —NO 2 , —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —CH═C(R n )(R n ), —OR n , —OC(O)R n , —OC(S)R n , —P(═O)HR n , —P(═O)R n R n , —PH(═O)OR n , —P(═O)(OR n ) 2 , —OP(═O)(OR n ) 2 , —C(O)H, —O(CO)OR n , —C(O)R n , —C(S)R n , —C(O)OR n , —C(S)OR n , —S(O)R n , —S(O) 2 R n , —C(O)NHR n , —C(S)NHR n , —C(O)NR n R n , —C(S)NR n R n , —S(O) 2 NHR n , —S(O) 2 NR n R n , —C(NH)NHR n , —C(NH)NR n R n , —NHC(O)R n , —NHC(S)R n , —NR n C(O)R n , —NR n C(S)R n , —NHS(O) 2 R n , —NR n S(O) 2 R n , —NHC(O)NHR n , —NHC(S)NHR n , —NR n C(O)NH 2 , —NR n C(S)NH 2 , —NR n S(O)NHR n , —NR n C(S)NHR n , —NHC(O)NR n R n , —NHC(S)NR n R n , —NR n C(O)NR n R n , —NR n C(S)NR n R n , —NHS(O) 2 NHR n , —NR n S(O) 2 NH 2 , —NR n S(O) 2 NHR n , —NHS(O) 2 NR n R n , —NR n S(O) 2 NR n R n , —NHR n , R n or —NR n R n , wherein each R n is independently selected from H, C 1-6 alkyl or aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl or cyclaoalkylalkyl; or two groups when attached to the same carbon or nitrogen atom are taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N or S, wherein the nitrogen or sulfur ring atoms are optionally oxidized, wherein the aliphatic or aromatic portion of R n is further optionally substituted with from 1-3 R h .

22 . The compound of any claims 1 - 21 , wherein R 3 is H, halogen, —CN, —CD 3 , deuterated, C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 3-8 cycloalkyl-C 1-4 alkyl, C 2-6 alkynyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl or wherein each R 3 is optionally substituted with from 1-3 R o members independently selected from halogen, vinyl, C 1-6 alkyl, —OH, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, —CN, —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , C 3-6 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein each R o is further independently optionally substituted with from 1-3 R h .

23 . The compound of any claims 1 - 22 , wherein R 4 is H.

24 . A pharmaceutical composition comprising a compound of any of claims 1 - 23 and a pharmaceutical acceptable excipient or carrier.

25 . A pharmaceutical composition comprising a compound of any of claims 1 - 23 and another therapeutic agent.

26 . A method for modulating bromodomain, said method comprising: administering to a subject in need thereof a compound of any of claims 1 - 23 or a composition of claim 24 or 25 .

27 . A method for modulating bromodomain, said method comprising: contacting a cell with a compound of any of claims 1 - 23 or a composition of claim 24 or 25 .

28 . A method for treating a subject suffering or at risk of a disease or condition mediated by a bromodomain, said method comprising:

administering to the subject in need thereof an effective amount of a compound of any of claims 1 - 23 or a composition of claim 24 or 25 .

29 . The method of claim 28 , wherein the disease or condition is selected from a cancer, a autoimmune, an inflammatory condition or a combination thereof.

30 . The method of any claims 26 - 29 , wherein the bromodomain is a member in the BET family.